瑞舒伐他汀在急性ST段抬高型心肌梗死介入治疗后的应用价值

Application value of rosuvastatin after interventional therapy for acute ST-segment elevation myocardial infarction

目的探讨瑞舒伐他汀在急性ST段抬高型心肌梗死(STEMI)介入治疗后的应用价值。方法将184例急性STEMI患者采用随机数字表法分为对照组和试验组,各92例。两组均行经皮冠状动脉介入治疗(PCI)后给予常规药物治疗,试验组加用瑞舒伐他汀治疗。比较两组治疗前、后的血脂指标、炎症因子及心肌损伤相关蛋白水平。结果治疗后,试验组的TG、TC、LDL-C、HDL-C、IL-6、TNF-α、hs-CRP、CK-MB、cTnI、BNP水平均优于对照组(P<0.05)。结论瑞舒伐他汀能显著改善急性STEMI患者PCI术后的血脂水平,降低患者血清炎症因子水平,减轻心肌细胞损伤程度。

Objective To investigate the application value of rosuvastatin after interventional therapy for acute ST-segment elevation myocardial infarction(STEMI). Methods A total of 184 patients with acute STEMI were divided into control group and experimental group according to random number table method, with 92 cases in each group. After percutaneous coronary intervention(PCI), routine drugs were given to both groups, and rosuvastatin was added to the experimental group. Before and after treatment, the levels of blood lipid indexs, inflammatory factors and myocardial injury related proteins were compared between the two groups. Results After treatment, the levels of TG, TC, LDL-C, HDL-C,IL-6, TNF-α, hs-CRP, CK-MB, cTnI and BNP in the experimental group were better than those in the control group(P <0.05). Conclusion Rosuvastatin can significantly improve the blood lipid level, and reduce the level of serum inflammatory factors and the degree of myocardial cell injury in acute STEMI patients after PCI.